NAVB
Navidea Biopharmaceuticals Inc.
NAVB
NAVB
Delisted
NAVB was delisted on the 5th of October, 2023.
30 hedge funds and large institutions have $364K invested in Navidea Biopharmaceuticals Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
83% less call options, than puts
Call options by funds: $1K | Put options by funds: $6K
Holders
30
Holding in Top 10
–
Calls
$1K
Puts
$6K
Top Buyers
| 1 | +$45K | |
| 2 | +$33K | |
| 3 | +$14.1K | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$260 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3 |
Top Sellers
| 1 | -$99.1K | |
| 2 | -$34.6K | |
| 3 | -$7.29K | |
| 4 |
VF
Virtu Financial
New York
|
-$4.26K |
| 5 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$2.61K |